Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Glycoanalytics-guided discovery of novel biomarkers and therapeutic glycoenzyme inhibitors for cancer

Ziel

Gastric (GC) and colorectal cancer (CRC) are major contributors to cancer-related deaths worldwide and current therapies lack efficacy. Thus, it is crucial to search for novel therapeutics to combat the increasing toll these cancers place on society globally. Glycosylation is the process by which complex carbohydrates (or glycans) are attached to lipids and proteins and is orchestrated by a suite of glycosyltransferases and glycosidases, collectively known as glycoenzymes. Glycosylation mediates a plethora of cellular processes such as cell-cell communication and cell adhesion andaberrant protein glycosylation is involved in cancer progression by influencing cell signalling, metastasis and immune evasion. Thus, glycosylation offers a largely overlooked class of biomolecules that hold promise as therapeutic targets. Taken together, this project aims to implement glycoanalytical approaches for the development of novel therapeutic strategies for GC and CRC treatment and reveal new insights into the roles of glycosylation in cancer biology. State-of-the-art analytical approaches based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) will be applied to develop comprehensive knowledge of the glycome and glycoproteome of GC and CRC cell lines, tissues and patient-derived organoids. The outputs from these comprehensive glycoprofiling exercises will reveal the key glycoenzymes to target with inhibitors and their therapeutic potential and mechanisms of action. Glycan biomarkers and glycoenzyme inhibitors will also be used in combination with currently approved therapeutic drugs for cancer such as monoclonal antibodies (e.g. Cetuximab) to evaluate combinatorial effects. Overall, this project will provide the most detailed and clinically relevant glycoprofiles for GC and CRC and will pioneer the application of these biomarkers in the GC and CRC therapeutic settings to reduce the global burden of these deadly cancers.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-MSCA-2025-PF

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO
Netto-EU-Beitrag
€ 207 183,12
Adresse
RUA ALFREDO ALLEN 208
4200-135 Porto
Portugal
Region
Continente Norte Área Metropolitana do Porto
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten